Neurocrine Biosci…
USUSDNeurocrine Biosciences Inc (MI:1NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Брой борси, на които се търгуват акциите на компанията: 3. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За компанията
- Уебсайт
- neurocrine.com
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Централа
- San Diego, United States
- Изпълнителен директор
- Kyle W. Gano
- Служители
- 2 500
- Основана
- 1992
- Акции в обращение
- 101.65 млн към 2026-07-22
- Свободно търгуеми акции
- 100.37 млн
- Пазарна капитализация
- 14.42 млрд USD
- Инсайдери
- 1.06%
- Институционални инвеститори
- 102.84%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- Правна форма
- XTIQ
- ISIN
- US64125C1099
- LEI
- 549300FECER0XBN49756
- FCF
- 870 млн USD
- Дълг
- 0
- Печалби и FCF — за 12-те месеца до 30.06.2026 (последният доклад на компанията).
Описание
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Новини тази седмица
Все още няма новини от сайта на компанията.
Най-големи притежатели
| Притежател | Дял | Акции | Дата на доклада |
|---|---|---|---|
| Blackrock Inc. | 13.49% | 13.71 млн | 2026-06-30 |
| JPMORGAN CHASE & CO | 6.29% | 6.4 млн | 2026-06-30 |
| Dodge & Cox Inc. | 5.49% | 5.58 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.89% | 4.97 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.47% | 4.55 млн | 2026-06-30 |
| State Street Corporation | 4.31% | 4.39 млн | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.9% | 3.96 млн | 2026-06-30 |
| AQR Capital Management,… | 3.76% | 3.82 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 3.46% | 3.52 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.14% | 3.19 млн | 2026-06-30 |
| Renaissance Technologies… | 2.3% | 2.34 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.27% | 2.3 млн | 2026-06-30 |
| Geode Capital Management… | 2.1% | 2.14 млн | 2026-06-30 |
| Two Sigma Investments, L… | 2.04% | 2.08 млн | 2026-06-30 |
| J.P. Morgan Mutual Fd. I… | 1.34% | 1.36 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 1.33 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.13% | 1.15 млн | 2026-06-30 |
| JPMorgan Trust II-JPMorg… | 1.1% | 1.12 млн | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.73% | 739 670 | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.72% | 735 342 | 2026-08-31 |
| GORMAN KEVIN CHARLES (Di… | ≈0.51% | 517 797 | 2026-09-11 |
| GANO KYLE W (Chief Execu… | ≈0.15% | 154 728 | 2026-09-11 |
| LYONS GARY A (Director) | ≈0.12% | 122 141 | 2026-05-21 |
| BENEVICH ERIC S. (Office… | ≈0.07% | 67 297 | 2026-09-11 |
| LIPPOLDT DARIN M (Office… | ≈0.06% | 56 793 | 2026-09-11 |
| RASTETTER WILLIAM H (Dir… | ≈0.04% | 43 678 | 2026-05-21 |
| ABERNETHY MATTHEW C (Chi… | ≈0.04% | 42 808 | 2026-09-14 |
| POPS RICHARD F (Director… | ≈0.04% | 37 798 | 2026-05-21 |
| ROBERTS EIRY WYN (Office… | ≈0.04% | 35 640 | 2025-02-14 |
| COOKE JULIE SMITH (Offic… | ≈0.02% | 24 025 | 2026-09-11 |
